Zimmer Biomet Holdings Inc
ZBH
Get informed when a big investor buys or sells
+ FollowMarket Cap$18.8B
Close$
Earnings Call Q2 2025
August 7, 2025 - AI Summary
Q2 Performance & Growth Outlook: Zimmer Biomet reported a 2.8% organic constant currency revenue growth in Q2 2025, with positive contributions from the U.S. Hips (up 5.2%) and Knees (up 1.7%). For the full year, the company raised its organic revenue growth guidance to 3.5%-4.5%, previously 3%-5%, and expects Paragon 28 to contribute an additional 270 basis points.
Adjusted Earnings Guidance: The company increased its adjusted EPS forecast for 2025 to $8.10-$8.30, from $7.90-$8.10, reflecting strong operational efficiencies, reduced tariff impacts, and favorable foreign exchange conditions. This suggests a commitment to profitability in a challenging market environment.
Strategic Acquisitions: The acquisition of Monogram Technologies was highlighted as a pivotal event for the company, aimed at advancing Zimmer Biomet’s robotics capabilities. The deal is expected to be neutral to adjusted EPS between 2025 and 2027, with potential revenue contributions beginning in 2027.
Exclusive for Stockcircle Pro members
Sign up
$275.34
179.4% upside
Current Fair Value
179.4% upsideUndervalued by 179.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $18.80 Billion |
|---|---|
| Enterprise Value | $25.87 Billion |
| Dividend Yield | $0.96 (0.97%) |
| Earnings per Share | $3.56 |
| Beta | 0.49 |
| Outstanding Shares | 192,200,000 |
Return
| Return on Equity | 6.39% |
|---|---|
| Return on Assets | 3.54% |
| Return on Invested Capital | 6.81% |
Valuation & Multiples
| P/E Ratio | 23.86 |
|---|---|
| PEG | - |
| Price to Sales | 2.24 |
| Price to Book Ratio | 1.52 |
| Enterprise Value to Revenue | 3.04 |
| Enterprise Value to EBIT | 19.21 |
| Enterprise Value to Net Income | 32 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.59 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$2.01
Average shareholder expectationRevenue Estimate
$2.13 B
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$1.88
Average shareholder expectationRevenue Estimate
$2.04 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 95.53% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.40%▼ 101.28% |
|---|---|
| Total Invested | $234.64M▼ 98.64% |
| Investors Holding | 197▼ 736.00% |
ESG Score
No data
About Zimmer Biomet Holdings Inc
17,000 employees
CEO: Bryan Hanson Zimmer Biomet Holdings, Inc., along with its various subsidiaries, is a prominent player in the global musculoskeletal healthcare industry, providing its specialized solutions across the Americas, Europe, the Middle East, Africa, and the...